Business

<< Previous   of   Next >>   ADVERTISEMENT   CONTACT THE HERALD Mike Benbow, Business Editor benbow@heraldnet.com   Published: Friday, March 21, 2008 Bothell's Seattle Genetics pitches drug combo Clinical trial starts for pair to fight 'preleukemia' By Eric Fetters Herald Writer BOTHELL -- Seattle Genetics is studying whether combining one of its engineered antibodies with a cancer drug could help patients with a condition that attacks the body's bone marrow. The Bothell-based biotechnology firm said Thursday it has begun a phase 1 clinical trial to test the safety and effectiveness of SGN-33 when it is taken with the cancer drug Revlimid to treat myelodysplastic syndromes, which disrupt bone marrow's production of blood cells. The trial is being conducted in concert with Celgene Corp., the maker of Revlimid. SGN-33 works by targeting the CD33 antigen, which is expressed in a number of blood-related cancers. The drug candidate already is in phase 2 tests as a treatment for acute myeloid leukemia and has received "orphan drug" status from the Food and Drug Administration for that use. That status, designed to encourage new drugs for relatively rare diseases, offers potential government funding and tax credits, as well as protection from competition. It makes sense to test the drug against myelodysplastic syndromes, because it is related to the leukemia already being targeted by Seattle Genetics, said Thomas Reynolds, the biotech's chief medical officer. "Patients with intermediate and high-risk MDS typically have a poor prognosis and their disease often transforms into acute myeloid leukemia, underscoring the need for a well-tolerated treatment option that can extend overall survival," Reynolds said in Thursday's announcement. According to the American Cancer Society, an estimated 10,000 to 15,000 new cases of MDS are diagnosed annually in the United States. The syndromes disrupt bone marrow function, usually decreasing the number of red and white blood cells and or platelets. About 30 percent of patients with the syndromes eventually develop leukemia. Because of that, MDS also is sometimes called "smoldering leukemia" or "preleukemia." SGN-33 is one of three drugs Seattle Genetics has in human-testing trials. The company's most advanced drug candidate is SGN-40, which is being developed with Genentech to treat non-Hodgkin lymphoma and multiple myeloma. Seattle Genetics' shares rose 26 cents, or 3 percent, Thursday to close at $8.96. Reporter Eric Fetters: 425-339-3453 or fetters@heraldnet.com.

1. Fighting foreclosure: How one couple got caught in mortgage crisis 2. Easy to steal, pricey to replace 3. 155-year boys club comes to an end 4. Monroe man's family remembers a life devoted to service 5. Future Seahawk? 6. No injuries in I-5 crash 7. Woman crossing street hit by car 8. Keep on ticking after you're dead 9. Hindus pray for peace at Bothell temple 10. Many Mexican migrants are heading home broke 2 - Top 10 Stories Most Talked about 3 - Top 10 Stories Most Emailed

• Was burglary suspect burglarized? • Food banks facing hard times • Council member resigns, heading to D.C. • Edmonds closes aid car loophole • Wildcats head to state semifinals • Thanksgiving served with an outpouring of generosity • King's takes third at 1A state tournament • School closures recommended • Raising school spirit at Shorewood • Stillaguamish Tribe’s Angel of the Winds Casino opens new addition Dec. ... • Building energy independence from the ground up